Canada approves insulin aspart biosimilar Trurapi

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Canada approves insulin aspart biosimilar Trurapi

Biosimilars/News | Posted 12/02/2021 1 Post your comment

Canada’s drug regulator, Health Canada, has approved the insulin aspart biosimilar Trurapi.

Trurapi is a biosimilar of Novo Nordisk’s NovoRapid (insulin aspart). Insulin aspart is a type of manufactured insulin used to treat type 1 and type 2 diabetes. It has a more rapid onset and a shorter duration of activity than normal human insulin.

Sanofi’s Trurapi was approved by Health Canada on 15 October 2020 as a solution for subcutaneous injection at a dose of 100 units/mL. It is the first insulin aspart biosimilar to be approved in Canada and is also Sanofi’s first biosimilar to be approved in the country.

Sanofi has also gained approval for its insulin aspart biosimilar in Australia, where it is called Truvelog [1], and in Europe, where it is called Insulin aspart Sanofi [2].

Related article
Biosimilars of insulin aspart

Biosimilars approved in Canada

LATIN AMERICAN FORUM – Coming soon! To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America. Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM – Próximamente! Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica. Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Australia approves etanercept and insulin aspart biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Feb 12]. Available from: www.gabionline.net/Biosimilars/News/Australia-approves-etanercept-and-insulin-aspart-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. EC approval for Sanofi’s insulin aspart biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Feb 12]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-Sanofi-s-insulin-aspart-biosimilar

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Health Canada